Corporate News
Polarean notes statement from Amphion Innovations
03 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that 750,000 shares in Polarean have been sold for partial repayment of Amphion's loan facility which was originally announced on 5 June 2014 and most recently amended as announced on 25 September 2019.
Following this sale, Amphion holds 15,972,523 ordinary shares of Polarean, representing 13.96% of the Company's issued share capital.
The full TR-1 disclosure is set out below.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuerandto the FCA in Microsoft Word format if possible)i | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Polarean Imaging plc | |||||
1b. Please indicate if the issuer is a non-UK issuer(please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification(please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify)iii: | ||||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Amphion Innovations plc | |||||
City and country of registered office (if applicable) | ||||||
4. Full name of shareholder(s)(if different from 3.)v | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reachedvi: | 2 October 2019 | |||||
6.Date on which issuer notified (DD/MM/YYYY): | 2 October 2019 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | |||
Resulting situation on the date on which threshold was crossed or reached | 13.96% | 114,438,600 | ||||
Position of previous notification (if
applicable) |
14.96% |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of shares
ISIN code (if possible) |
Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
GB008BVVT4H71 | 15,972,523 | 13.96% | |||||||
SUBTOTAL 8. A | 15,972,523 | 13.96% |
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expiration datex |
Exercise/ Conversion Periodxi |
Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 |
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of financial instrument | Expiration datex |
Exercise/ Conversion Periodxi |
Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
SUBTOTAL 8.B.2 |
9. Information in relation to the person subject to the notification obligation(please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | X | |||
Fullchain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv(please add additional rows as necessary) | ||||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
10. In case of proxy voting, please identify: | |
Name of the proxy holder | |
The number and % of voting rights held | |
The date until which the voting rights will be held |
11. Additional informationxvi | ||||
Place of completion | London, UK |
Date of completion | 2 October 2019 |
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
Richard Morgan, Chairman | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Latest News
-
Virtual Investor Day
25 September 2024 -
Half-year Report
04 September 2024 -
Appointment of Alan Huang, Ph.D., as Vice President of Sales
03 September 2024
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts